

Michael S Chang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7389292/publications.pdf>

Version: 2024-02-01

29
papers

183
citations

1478505

6
h-index

1199594

12
g-index

29
all docs

29
docs citations

29
times ranked

403
citing authors

#	ARTICLE	IF	CITATIONS
1	Sociodemographic determinants of teledermatology acceptability. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1392-1394.	1.2	4
2	Racial and ethnic differences in the surgical treatment of dermatofibrosarcoma protuberans: A retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 245-247.	1.2	3
3	Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 766-773.	1.2	6
4	Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1301-1308.	1.2	3
5	Cutaneous Squamous Cell Carcinoma: The Frontier of Cancer Immunoprevention. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 101-119.	22.4	18
6	Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy. <i>British Journal of Dermatology</i> , 2022, 187, 424-426.	1.5	1
7	Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 21-23.	2.8	0
8	Cutaneous adverse events to immune checkpoint inhibitors in pediatric populations: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1587-1589.	1.2	2
9	Patterns of cutaneous immune-related adverse events in adults and children with advanced sarcoma: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2021, 184, 363-365.	1.5	0
10	Modified peripheral and central Mohs micrographic surgery for improved margin control in extramammary Paget disease. <i>JAAD Case Reports</i> , 2021, 7, 71-73.	0.8	8
11	Impact of ethnicity on the diagnosis and management of cutaneous toxicities from immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 851-854.	1.2	6
12	Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies. <i>Cancer Prevention Research</i> , 2021, 14, 77-84.	1.5	9
13	Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa642.	0.9	6
14	Association between common medication triggers and severity of cutaneous immune-related adverse events. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
15	Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. <i>JAMA Dermatology</i> , 2021, 157, 577.	4.1	31
16	Impact of systemic corticosteroids for cutaneous immune-related adverse events on survival outcomes in patients with advanced cancer: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14523-e14523.	1.6	0
17	Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced Cancer. <i>JAMA Dermatology</i> , 2021, 157, 599.	4.1	4
18	Relationship between insurance status and diagnosis of cutaneous immune-related adverse events.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18535-e18535.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. <i>British Journal of Dermatology</i> , 2021, 185, 627-635.	1.5	12
20	Risk factors for thick melanoma among veterans: A cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1766-1769.	1.2	5
21	Limitations of morphology-based management for immune checkpoint inhibitor-related cutaneous adverse events. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e281-e282.	1.2	2
22	Advanced care planning, code status and end-of-life care in patients with bullous pemphigoid. <i>British Journal of Dermatology</i> , 2021, , .	1.5	0
23	Sunscreen use is not associated with increased blood concentrations of benzene among adults in the United States: Data from the National Health and Nutrition Examination Survey 2003-2006 and 2009-2018. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
24	Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: a retrospective cohort analysis. <i>British Journal of Dermatology</i> , 2021, , .	1.5	1
25	Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid. <i>European Journal of Cancer</i> , 2021, 159, 34-37.	2.8	5
26	Changes in melanoma care practices during the COVID-19 pandemic: a multi-institutional cross-sectional survey. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	2
27	Discordance between recommended and delivered therapies for immunotherapy-associated cutaneous toxicities in pediatric populations. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28653.	1.5	0
28	Concurrent <i>Trypanosoma cruzi</i> and Cytomegalovirus Reactivation in an Immunosuppressed Patient With Limited Cutaneous Systemic Sclerosis. <i>American Journal of Dermatopathology</i> , 2020, Publish Ahead of Print, .	0.6	1
29	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294.	1.2	54